Physicians' Academy for Cardiovascular Education

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Meeting report of a PACE-CME symposium at ESC Heart Failure 2022 on initiating SGLT2i in HFrEF.

E-learning When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this program, three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022
Watch a discussion by three experts on initiating SGLT2i in HFrEF.

Watch a discussion by three experts on initiating SGLT2i in HFrEF.

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD
Prof. Solomon talks about unanswered questions with SGLT2 inhibitors and discusses the study design of the DELIVER, a phase 3 trial with dapagliflozin in patients with HF and LVEF>40%.

Prof. Solomon talks about unanswered questions with SGLT2 inhibitors and discusses the study design of the DELIVER, a phase 3 trial with dapagliflozin in patients with HF and LVEF>40%.

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD
Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD
Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.

Slides: Expanding evidence on SGLT2 Inhibition: Where are we now and what can we expect?

Slides (presentation) - May 22, 2022 - Slides as educational service to PACE members and meeting participants.
Find here the slides of the presentation by Prof. Scott Solomon, MD, part of an educational series entitled

Find here the slides of the presentation by Prof. Scott Solomon, MD, part of an educational series entitled "When to start using SGLT2i in HFrEF - Initiating guideline recommended treatment options".

Slides: The clinical challenges of initiating guideline recommended therapy in heart failure: What are the barriers to treatment?

Slides (presentation) - June 22, 2022 - Slides as educational service to PACE members and meeting participants.
Find here the slides of the presentation by Prof. John McMurray, MD, part of an educational series entitled

Find here the slides of the presentation by Prof. John McMurray, MD, part of an educational series entitled "When to start using SGLT2i in HFrEF - Initiating guideline recommended treatment options".

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options